This site is intended for US
healthcare professionals only.

Important Safety Information Prescribing Information

For patients with multiple myeloma after 1 prior therapy

NINLARO® (ixazomib) - Multiple Myeloma Treatment
The approval of the NINLARO® (ixazomib) regimen (NINLARO+lenalidomide+dexamethasone) was based on a statistically significant ~6 month improvement in median progression-free survival vs the placebo regimen (placebo+lenalidomide+dexamethasone) (median: 20.6 vs 14.7 months [95% CI, 17.0-NE and 95% CI, 12.9-17.6, respectively]; HR=0.74 [95% CI, 0.587-0.939]; P=0.012).

The first and only oral proteasome inhibitor

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.